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Introduction
Hemoglobin SC (HbSC) disease is a heterozygous condi-
tion in which similar concentrations of hemoglobin S (HbS)
and hemoglobin C (HbC) coexist. The unique pathogenic
characteristic of HbSConline disease is that HbC has the abil-
ity to induce erythrocyte dehydration and intracellular crystal
formation.1,2 Erythrocytes containing HbC have high K-Cl
cotransport activity with high K+ and water efflux, leading to
cellular dehydration; this results in erythrocytes that are
denser than normal red blood cells, microcytic, hyperchromic
and have a markedly increased mean corpuscular hemoglobin
concentration.1-4 While HbC in homozygosity produces only
a mild hemolytic anemia, the coexistence of HbC and HbS
results in a significantly more serious disorder, as the dehy-
dration induced by HbC enhances the pathogenic properties
of HbS.1,2 Hemoglobin SC disease is considered to be a milder
hemoglobinopathy than sickle cell anemia (SCA), the
homozygous state of HbS (HbSS). All of the clinical compli-
cations seen in SCA are also present in HbSC disease, but in
the latter they generally occur less frequently and are less
severe.1,5
There appears to be an increased risk of thromboembolic
events in HbSC disease. Studies of sickle cell disease, includ-
ing both HbSS and HbSC patients in their study cohorts, have
shown elevated rates of venous thromboembolism, especial-
ly pulmonary embolism.6,7 An autopsy study showed that
pulmonary emboli/thrombi are the second most important
cause of mortality in HbSC patients, responsible for 13.6% of
deaths, and are a more frequent cause of death in HbSC dis-
ease than in SCA.8 Arterial thromboembolic events are also
prevalent, with a higher risk of ischemic stroke in patients
than in the general population.9 There is clear evidence of a
hypercoagulability state in SCA, with nearly every element
of hemostasis altered in the pro-coagulant direction.10-17 While
coagulation abnormalities have been extensively studied in
SCA, very little is known about the hemostatic state specifi-
cally in HbSC disease. The aim of the present study was to
evaluate coagulation activation markers in HbSC disease and
compare them with those in HbSS patients and normal con-
trols. We also evaluated associations of hypercoagulability
markers with clinical complications and with markers of
endothelial activation, hemolysis and inflammation.
Methods
Patients 
This was a cross-sectional observational study that included adult
HbSC and HbSS patients (aged >18 years) who consecutively attend-
ed the Hematology and Hemotherapy Center of the University of
Campinas (UNICAMP, Brazil) during the period from September 2011
to January 2013. Only patients in steady state who had not had any
type of painful crisis, hospitalization or blood transfusions in the pre-
ceding 3 months were included. None of the HbSC and HbSS patients
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Hemoglobin SC disease is a very prevalent hemoglobinopathy; however, very little is known about this condition
specifically. There appears to be an increased risk of thromboembolic events in hemoglobin SC disease, but studies
evaluating the hemostatic alterations are lacking. We describe the findings of a cross-sectional observational study
evaluating coagulation activation markers in adult patients with hemoglobin SC, comparing them with those in
sickle cell anemia patients and healthy controls. A total of 56 hemoglobin SC and 39 sickle cell anemia patients
were included in the study, all in steady state, and 27 healthy controls. None of the patients was taking hydrox-
yurea. Hemoglobin SC patients had a significantly up-regulated relative expression of tissue factor, as well as eleva-
tions in thrombin-antithrombin complex and D-dimer, in comparison to controls (P<0.01). Hemoglobin SC
patients had lower tissue factor expression, and thrombin-antithrombin complex and D-dimer levels when com-
pared to sickle cell anemia patients (P<0.05). Markers of endothelial activation (soluble thrombomodulin and sol-
uble vascular cell adhesion molecule-1) and inflammation (tumor necrosis factor-alpha) were both significantly ele-
vated in hemoglobin SC patients when compared to controls, being as high as the levels seen in patients with sick-
le cell anemia. Overall, in hemoglobin SC patients, higher hemolytic activity and inflammation were associated
with a more intense activation of coagulation, and hemostatic activation was associated with two very prevalent
chronic complications seen in hemoglobin SC disease: retinopathy and osteonecrosis. In summary, our results
demonstrate that hemoglobin SC patients have a hypercoagulable state, although this manifestation was not as
intense as that seen in sickle cell anemia. 
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ABSTRACT
included in the study was being treated with hydroxyurea.
Patients who were on anticoagulation were excluded. A total of 56
HbSC patients were compared to a population of 39 HbSS
patients, of whom 15 were described in a previous study.17 We also
selected 27 healthy age-matched HbAA controls. The University’s
ethics committee approved the study and all of the patients includ-
ed signed a written informed consent form.
Venous blood samples for all of the study analyses, including
peripheral blood counts and hemolysis markers, were obtained
simultaneously. 
Tissue factor mRNA expression in leukocytes
Tissue factor (TF) expression was analyzed by real time quantita-
tive polymerase chain reaction (qPCR) assays performed on the
ABI 7500 Sequence Detection System (Applied Biosystems).
cDNA samples were reverse transcribed from total leukocyte
RNA, isolated using Trizol Life Reagents (Invitrogen). The reverse
transcription reaction was performed using a RevertAid™ First
Strand cDNA Synthesis Kit (MBI Fermentas). Maxima Syber green
qPCR master mix (MBI Fermentas) was used for real-time detec-
tion of amplification. The TF gene was analyzed in parallel with
the b-Actin gene, used as an endogenous control, and all samples
were run in triplicate. A sample from one of the controls was used
as the calibrator. Relative quantification of TFmRNA was normal-
ized by the cycle threshold (Ct) of b-Actin (DCT), calculated using
the equation, 2− DDCT.18 The dissociation protocol was performed at
the end of each run to check for non-specific amplification.
Primers for TF and b-Actin were both designed using Primer
Express.
Markers of thrombin generation, endothelial activation
and inflammation
Thrombin-antithrombin complex (TAT) and D-dimer are
known thrombin generation markers and were measured as final
markers of coagulation activation in plasma. Endothelial activation
was evaluated through quantification of the levels of soluble
thrombomodulin and soluble vascular cell adhesion molecule-1
(sVCAM-1). Tumor necrosis factor-alpha (TNF-a) and interleukin
8 (IL-8) were assessed as pro-inflammatory markers. All of these
markers were measured in duplicate, using commercially available
enzyme-linked immunosorbent assay kits: TAT (Enzygnost®,
Siemens, Marburg, Germany), D-dimer (Sekisui Imuclone® D-
dimer, Stamford, CA, USA), soluble thrombomodulin (IMU-
BIND®, American Diagnostica Inc., Stamford, CT, USA), sVCAM-
1 (Quantikine®, R&D Systems, Minneapolis, MN, USA) and ultra-
sensitive TNF-a and IL-8 (TNF-a US and IL-8 US, Invitrogen,
Camarillo, CA, USA). 
Statistical analyses
The expression of TF mRNA, TAT, D-dimer, soluble thrombo-
modulin, sVCAM-1, IL-8 and TNF-a were compared among the
two groups of patients and the control group using Mann-
Whitney U tests. Categorical variables were compared by the
Fisher exact test. Spearman rank correlation coefficient was used
to analyse bivariate associations between TF expression, TAT, D-
dimer, soluble trombomodulin, sVCAM-1, IL-8, TNF-a, white
blood cell counts, hemolysis markers, and age.
Statistical analyses were performed using Prism 6 (GraphPad
Software). P values ≤ 0.05 were considered statistically significant.
Results
Patients’ characteristics
A total of 56 steady state HbSC and 39 HbSS patients
were included in the study. Clinical and laboratory data
were collected from all patients (Table 1). None of the
patients in either of the groups was being treated with
hydroxyurea. Patients in the HbSC group were older than
the HbSS patients. Histories of retinopathy and
osteonecrosis were much more frequent in the HbSC
group. Pulmonary hypertension and autosplenectomy
(absence of a spleen visible by ultrasound) were more
prevalent in the HbSS patients. The prevalence of other
clinical sickling complications was similar in the two
groups of patients, probably due to the fact that only
HbSS patients without an indication for hydroxyurea
(who represent a subset of HbSS patients with a milder
phenotype) were included in the study. As expected,
when compared to HbSS patients, HbSC patients had sig-
nificantly higher hemoglobin and hematocrit levels, lower
levels of hemolysis markers (lactate dehydrogenase, indi-
rect bilirubin, reticulocyte counts) and lower leukocyte,
monocyte and platelet counts. 
Tissue factor expression is elevated in HbSC disease
Quantitative PCR analysis showed an up-regulation of
TF mRNA relative expression in the leukocytes of HbSC
patients, in comparison to that in the leukocytes of
healthy controls (1.7 in HbSC patients versus 0.9 in con-
trols, P=0.005). When compared to leukocytes from HbSS
patients, those from HbSC patients had lower TF relative
Table 1. Clinical and laboratory characteristics of the hemoglobin SC and
sickle cell anemia patients.
SC SS P1
n=56 n=39
Clinical characteristics:
Age (years)2 40 (33, 49) 36 (26, 43) 0.004
Gender: male/female3 25(45) / 31(55) 10(26) / 29(74) 0.08
a-thalassemia trait3,4 13 (31) 8 (28) 0.8
Clinical sickling complications3
Acute chest syndrome 7 (13) 3 (8) 0.7
Stroke 2 (4) 3 (8) 0.4
Leg ulcers 2 (4) 5 (13) 0.1
Retinopathy5 32 (65) 7 (24) 0.0009
Osteonecrosis 22 (39) 4 (10) 0.004
Pulmonary hypertension6 4 (9) 8 (27) 0.05
Autosplenectomy7 21 (45) 21 (84) 0.002
Laboratory characteristics2:
Lactate dehydrogenase (U/L) 453 (403, 571) 1092 (850, 1365) <0.0001
Indirect bilirubin (mg/dL) 1.0 (0.8, 1.3) 3.1 (1.7, 5.1) <0.0001
Hemoglobin(g/dL) 12 (10.5, 12.9) 7.4 (6.8, 8.5) <0.0001
Hematocrit (%) 33.9 (30.4, 37.3) 21.5 (19.5, 24.3) <0.0001
Mean corpuscular volume (fL) 78 (74, 83) 90 (86, 96) <0.0001
Absolute reticulocyte count (x109/L) 177.5 (138, 251) 306 (249, 429) <0.0001
Absolute leukocyte count (x109/L) 8.1 (6.6, 9.8) 10.9 (9, 12.7) <0.0001
Absolute neutrophil count (x109/L) 4.7 (3.4, 5.9) 5.2 (4.1, 6.6) 0.07
Absolute monocyte count (x109/L) 0.5 (0.3, 0.7) 1.0 (0.6, 1.3) <0.0001
Platelet count (x109/L) 343 (185, 439) 420 (337, 530) 0.003
SC: hemoglobin SC patients; SS: hemoglobin SS patients. 1All P values are two-tailed. The
patients’ ages and laboratory results were compared using the Mann-Whitney U test. The cate-
gorical variables were compared using the Fisher exact test.  2Data presented as: median (25th,
75th percentiles). 3Data presented as: number (%). 4a-thalassemia trait: -3.7kb deletion (-a 3.7).
Results were available for 42 patients in the SC group and 29 patients in the SS group. 5Data
regarding retinopathy were available for 49 patients in the SC group and 29 patients in the SS
group. 6Pulmonary hypertension was screened by echocardiogram and defined by a tricuspid
regurgitation velocity greater than 2.5 m/s. Data regarding pulmonary hypertension were avail-
able for 45 patients in the SC group and 30 patients in the SS group. 7Autosplenectomy was
defined as absence of a spleen visible by ultrasound. Data regarding autosplenectomy were
available for 47 patients in the SC group and 25 patients in the SS group.
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expression (1.7 in HbSC patients versus 3.4 in HbSS
patients, P=0.0001) (Figure 1A, Table 2).
Elevation of coagulation activation markers in HbSC
disease
The thrombin generation markers TAT and D-dimer
were both significantly elevated in HbSC patients, in com-
parison to those in controls (TAT: 4.2 mg/mL in HbSC
patients versus 2.4 mg/mL in controls, P<0.0001; D-dimer:
710 ng/mL in HbSC patients versus 150 ng/mL in controls,
P<0.0001). As expected, TAT and D-dimer levels were
lower in HbSC than in HbSS (TAT: 4.2 mg/mL in HbSC
patients versus 9.5 mg/mL in HbSS patients, P<0.0001; D-
dimer: 710 ng/mL in HbSC patients versus 1643 ng/mL in
HbSS patients, P=0.0004) (Figures 1B,C; Table 2).
Raised levels of markers of inflammation
and endothelial activation markers in HbSC disease
Plasma levels of soluble thrombomodulin, a marker of
endothelial activation, were significantly elevated in
HbSC patients, compared to those in healthy controls (3.2
ng/mL versus 2.6 ng/mL, respectively, P=0.004) and similar
to the levels observed in HbSS patients (3.2 ng/mL in
HbSC patients versus 3.5 ng/mL in HbSS patients, P=0.1)
(Figure 1D). Similarly, sVCAM-1 serum levels were higher
in HbSC patients than in controls (1137 ng/mL versus 862
ng/mL, respectively, P=0.002), but lower than in HbSS
patients (1137 ng/mL in HbSC patients versus 1492 ng/mL
in HbSS patients, P=0.0007) (Figure 1E; Table 2).
The inflammatory markers evaluated were TNF-a and
IL-8. Serum TNF-a levels were significantly higher in HbSC
patients than in controls (2.7 pg/mL versus 0 pg/mL, respec-
tively, P<0.0001), being as high as the levels seen in HbSS
(2.7 pg/mL in HbSC patients versus 2.7 pg/mL in HbSS
patients, P=1.0) (Figure 1F). On the other hand, serum IL-8
levels were similar in HbSC patients and controls (2.5
pg/mL versus 2.3 pg/mL, respectively, P=0.2), and also simi-
lar to the levels in HbSS (2.5 pg/mL in HbSC patients versus
2.8 pg/mL in HbSS patients, P=0.5) (Figure 1G; Table 2).
Correlations of coagulation markers with hemolysis,
inflammation and endothelial activation in HbSC
patients 
We evaluated the associations between the hypercoag-
ulability markers (TF mRNA expression, TAT, D-dimer)
and hemolysis (hemoglobin, hematocrit, lactate dehydro-
M.P. Colella et al.
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Figure 1. Coagulation, endothe-
lial and inflammation markers
in hemoglobin SC disease.
Tissue factor (TF) relative expres-
sion in leukocytes, markers of
coagulation [thrombin-
antithrombin complex (TAT) and
D-dimer], endothelial activation
[soluble thrombomodulin (s-
thrombomodulin) and soluble
vascular cell adhesion molecule-
1 (sVCAM-1)], and inflammation
[tumor necrosis factor-alpha
(TNF-a) and interleukin 8 (IL-8)]
in controls, hemoglobin SC
(HbSC) patients and sickle cell
anemia (HbSS) patients. The
numbers of patients studied are
indicated in each panel. P-val-
ues resulting from the compari-
son of two groups (indicated
with bars) are shown: **P<0.01,
***P<0.001, ****P<0.0001.
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genase, indirect bilirubin, reticulocyte counts), endothelial
activation (soluble thrombomodulin, sVCAM-1), inflam-
mation markers (TNF-a, IL-8, leukocyte, neutrophil and
monocyte counts), and age in the HbSC cohort (Table 3).
Significant positive correlations were identified between:
TF mRNA levels and sVCAM-1 and monocyte counts;
TAT and lactate dehydrogenase, reticulocyte, leukocyte,
monocyte and platelet counts; D-dimer and lactate dehy-
drogenase, reticulocyte and monocyte counts. Overall,
higher hemolytic activity and inflammation were associat-
ed with more intense activation of coagulation in HbSC
patients.
Associations of coagulation markers and clinical 
complications in HbSC patients
In the HbSC cohort, we analyzed the associations
between coagulation markers (TFmRNA expression, TAT,
D-dimer) and history of clinical complications. We com-
pared the levels of each marker in subjects with or with-
out the following clinical complications: stroke, acute
chest syndrome, retinopathy, osteonecrosis, pulmonary
hypertension, leg ulcers and autosplenectomy (Table 4).
HbSC patients with retinopathy had higher levels of TAT
and D-dimer than those in patients without this complica-
tion (TAT: 4.7 mg/mL versus 3.9 mg/mL, P=0.04; D-dimer:
852 ng/mL versus 600 ng/mL; P=0.01). TAT levels were
also higher in patients with a history of osteonecrosis than
in patients without this manifestation (4.6 mg/mL versus
3.9 mg/mL, P=0.04). Patients with autosplenectomy had
higher levels of TAT and D-dimer (TAT: 4.8 mg/mL versus
3.8 mg/mL, P=0.005; D-dimer: 870 ng/mL versus 616
ng/mL; P=0.006). The prevalence of some of the clinical
complications, such as stroke, acute chest syndrome, pul-
monary hypertension and leg ulcers, was very low in this
cohort, which might have affected this analysis.
Discussion
This study demonstrates that patients with HbSC dis-
ease have a hypercoagulable state. When compared to
normal controls, HbSC patients showed up-regulation of
leukocyte TF expression, the main physiological initiator
of coagulation in vivo. Confirming the biological relevance
of TF up-regulation, levels of thrombin generation markers
TAT and D-dimer were also significantly higher in the cir-
culation of HbSC patients than in normal controls.
Although levels of TF expression, TAT and D-dimer were
significantly elevated, demonstrating that there is activa-
tion of coagulation in HbSC disase, these parameters were
not as elevated as those seen in HbSS patients; when com-
pared to HbSS patients, HbSC patients had lower TF
expression, and lower TAT and D-dimer levels. It is impor-
tant to emphasize that the HbSS patients included in this
study were not taking hydroxyurea, so there was no inter-
ference from this treatment with coagulation activation
parameters. We have previously shown that hydroxyurea
treatment is associated with reductions in hypercoagula-
bility markers in SCA patients17 and, thus, the inclusion of
patients on hydroxyurea therapy would have affected the
comparison of results.
Previous studies have evaluated hypercoagulability
markers in sickle cell disease, including both patients with
SCA and those with HbSC disease.10,11,13-16,19-22 In some of
these studies, the authors described differences between
Table 2. Tissue factor expression, markers of coagulation, endothelial and inflammation activation in controls, hemoglobin SC and sickle cell anemia
patients.
Controls SC SS P1 P1
n  Median n Median n Median SC vs. Controls SC vs. SS
(25th, 75th percentiles) (25th, 75th percentiles) (25th, 75th percentiles)
Tissue factor2 27 0.9 (0.4, 1.5) 37 1.7 (0.9, 3.2) 29 3.4 (2.6, 6.8) 0.005 0.0001
TAT (mg/mL) 23 2.4 (1.9, 3.3) 39 4.2 (3.3, 5.9) 33 9.5 (6.4, 13.9) <0.0001 <0.0001
D-dimer (ng/mL) 15 150 (104, 225) 38 710 (596, 1155) 21 1643 (1058, 2440) <0.0001 0.0004
sVCAM-1 (ng/mL) 10 862 (798, 982) 23 1137 (1002, 1364) 20 1492 (1158, 1651) 0.002 0.0007
sThrombomodulin (ng/mL) 21 2.6 (2.2, 3) 56 3.2 (2.6, 3.8) 31 3.5 (2.8, 3.9) 0.004 0.1
TNF-a (pg/mL) 21 0 (0, 0.06) 27 2.7 (1.3, 4.5) 27 2.7 (1.1, 5.0) <0.0001 1.0
Interleukin-8 (pg/mL) 24 2.3 (1.9, 2.9) 36 2.5 (2.1, 4.1) 27 2.8 (2.3, 3.6) 0.2 0.5
SC: patients with hemoglobin SC disease; SS: patients with hemoglobin SS (sickle cell anemia); TAT: thrombin-antithrombin complex; sVCAM-1: soluble vascular cell adhesion molecule-1;
sThrombomodulin: soluble thrombomodulin; TNF-a: tumor necrosis factor-alpha. All P values are two-tailed and calculated using the Mann-Whitney U test. 2Tissue factor relative expression
evaluated by quantitative PCR.
Table 3. Correlations of TF expression and coagulation markers with hemoly-
sis, endothelial activation and inflammation markers in hemoglobin SC
patients.
TF1 TAT (mg/mL) D-dimer 
r (P)2 r (P) 2 (ng/mL)
r (P) 2
sVCAM-1 (ng/mL) 0.64 (0.02) -0.02 (0.96) -0.37 (0.17)
sThrombomodulin (ng/mL) -0.31 (0.87) -0.21 (0.20) -0.21 (0.19)
Interleukin-8 (pg/mL) 0.24 (0.26) 0.36 (0.06) 0.07 (0.76)
TNF-a (pg/mL) -0.04 (0.88) 0.03 (0.88) -0.07 (0.76)
Lactate dehydrogenase (U/L) -0.21 (0.44) 0.63 (<0.0001) 0.50 (0.001)
Indirect bilirubin (mg/dL) -0.30 (0.67) 0.20 (0.28) 0.01 (0.99)
Hemoglobin (g/dL) 0.08 (0.65) -0.26 (0.11) 0.06 (0.72)
Hematocrit (%) -0.18 (0.33) -0.30 (0.06) -0.02 (0.89)
Absolute reticulocyte count (x109/L) -0.11 (0.51) 0.40 (0.01) 0.45 (0.004)
Absolute leukocyte count (x109/L) 0.04 (0.83) 0.50 (0.001) 0.20 (0.21)
Absolute monocyte count (x109/L) 0.40 (0.01) 0.39 (0.01) 0.32 (0.04)
Absolute neutrophil count (x109/L) -0.08 (0.65) 0.20 (0.22) 0.06 (0.73)
Platelet count (x109/L) 0.15 (0.37) 0.49 (0.001) 0.19 (0.24)
Age 0.18 (0.28) 0.03 (0.88) -0.02 (0.89)
TF: tissue factor; TAT: thrombin-antithrombin complex; sVCAM-1: soluble vascular cell adhesion
molecule-1; sThrombomodulin: soluble thrombomodulin; TNF-a: tumour necrosis factor-alpha.
1TF relative expression evaluated by quantitative PCR. 2Spearman rank correlation coefficient
(r) was used to analyze bivariate associations and all P values are two-tailed.Statistically sig-
nificant results are shown in italics.
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HbSC and SCA patients, but the numbers of HbSC
patients included were always very low (n<18) and the
results were very variable.10,11,19-22 Since the focus of these
studies was not HbSC disease, only a few compared the
HbSC patients with normal controls.11,19,21,22 When this
comparison was made, the results were variable and no
conclusions could be drawn. It is important to emphasize
that, since our study was focused specifically on HbSC
disease, we included a large cohort of these patients
(n=56), whereas only very small numbers were included in
the previous studies (<18 cases).10,11,19,21,22 Since we included
a larger number of patients, we were able to evaluate asso-
ciations of hyperoagulability markers with clinical compli-
cations in HbSC patients.
Our results suggest that hemostatic activation may be
involved in two very prevalent chronic complications seen
in HbSC disease; retinopathy and osteonecrosis. Patients
with these manifestations had higher levels of thrombin
generation markers. This might reflect a causal relation-
ship between hypercoagulability and the development of
these complications or, alternatively, simply reflect more
severe disease in these patients. Another finding in our
HbSC cohort was that patients with autosplenectomy had
raised TAT and D-dimer levels, probably due to the faster
rate of intravascular hemolysis and elevated leukocyte and
platelet counts. 
In our cohort of HbSC patients, endothelial activation,
evaluated by the levels of soluble thrombomodulin and
sVCAM-1, was very intense, almost comparable to that
found in SCA patients. In previous studies, similar
sVCAM-1 levels were found in these two groups of
patients, with lower soluble P-selectin and E-selectin in
HbSC disease.19,23 Despite the findings of a significant
degree of endothelial activation in HbSC patients, our cor-
relation analyses showed a positive correlation of
sVCAM-1 and TF expression, but did not reveal any asso-
ciation between soluble thrombomodulin levels and coag-
ulation activation markers. This finding differs from that
in SCA, in which TF expression was significantly, positive-
ly correlated with soluble thrombomodulin level.17
We assessed the inflammatory activity in HbSC patients
by measuring serum TNF-a and IL-8 levels. With regards
to IL-8, no difference was found between levels in the two
groups of patients or controls. On the other hand, TNF-a
levels were significantly higher in HbSC patients, reaching
the same levels seen in SCA patients, and both groups of
patients had higher levels than those in controls. More
importantly, our correlation analyses demonstrated that
inflammation, indicated by leukocyte and monocyte
counts, is positively associated with coagulation activation
markers and possibly contributes to the development of
the hypercoagulability state in patients with HbSC dis-
ease. Although HbSC patients were significantly older
than HbSS patients, coagulation activation markers,
including TF expression, TAT and D-dimer levels, were
not significantly correlated with age.
A faster rate of hemolysis, demonstrated by higher retic-
ulocyte counts and lactate dehydrogenase levels, also cor-
related positively with higher levels of coagulation activa-
tion markers in HbSC patients. The pathophysiological
link between hemolysis and hemostatic activation is prob-
ably heme, a product of intravascular hemolysis, which is
capable of inducing TF expression by endothelial cells and
inducing neutrophil extracellular trap formation in sickle
cell disease.24,25 Similarly to observations in SCA, the
hypercoagulability state encountered in HbSC disease
seems to be associated with inflammation and hemoly-
sis.17,19,26 Thus, our results demonstrate similarities between
the pathophysiological mechanisms involved in the acti-
vation of coagulation in HbSC disease and SCA. However,
M.P. Colella et al.
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Table 4. Associations between coagulation markers and clinical complications in hemoglobin SC disease.
Variable Clinical complication                                                  Yes                                                           No                                       P1
                                                                    N.                        Median                         N.                     Median                       
Tissue factor2 Stroke                                                                        0                                  NA                                   37                              1.7                              NA
Acute chest syndrome                                           4                                  1.3                                   33                              1.7                              0.8
Pulmonary hypertension3                                      2                                  1.0                                   28                              1.8                              NA
Leg ulcers                                                                 2                                  3.5                                   35                              1.7                              NA
Osteonecrosis                                                        16                                 1.9                                   19                              1.7                              0.2
Retinopathy                                                             22                                 1.6                                   12                              2.1                              0.3
Autosplenectomy4                                                  12                                 2.2                                   20                              1.4                              0.2
TAT (mg/mL) Stroke                                                                        2                                  3.7                                   37                              4.2                              0.5
Acute chest syndrome                                           2                                  3.5                                   37                              4.2                              0.4
Pulmonary hypertension3                                      2                                  5.2                                   31                              4.2                              0.8
Leg ulcers                                                                 2                                  5.6                                   37                              4.2                              0.3
Osteonecrosis                                                        17                                 4.6                                   20                              3.9                             0.04
Retinopathy                                                             26                                 4.7                                   13                              3.9                             0.04
Autosplenectomy4                                                  18                                 4.8                                   19                              3.8                            0.005
D-dimer (ng/mL) Stroke                                                                        2                                  519                                   36                              778                              0.1
Acute chest syndrome                                           5                                 1135                                  33                              699                              0.1
Pulmonary hypertension3                                      3                                  666                                   30                              707                              0.8
Leg ulcers                                                                 1                                 2220                                  37                              709                              NA
Osteonecrosis                                                        16                                 777                                   19                              684                              0.4
Retinopathy                                                             22                                 852                                   11                              600                             0.01
Autosplenectomy4                                                  17                                 870                                   13                              616                            0.006
TAT: thrombin-antithrombin complex; NA: not applicable. 1All P values are two-tailed and calculated using the Mann-Whitney’s U test. 2Tissue factor relative expression evaluated by
quantitative PCR. 3Pulmonary hypertension was screened by echocardiogram and defined by a tricuspid regurgitation velocity > 2.5m/s. 4Autosplenectomy was defined as absence
of a visible spleen by ultrasound. Statistically significant results are shown in italics.
we believe that there are probably additional mechanisms
that are specific to HbSC disease and require further inves-
tigation, such as hyperviscosity and other aspects unique
to HbSC disease. 
In order to obtain an accurate evaluation of the associa-
tion between TF expression with functional coagulation
activation markers, as well as between additional coagula-
tion, inflammation and hemolysis markers, we only includ-
ed data obtained from samples collected at the same time-
point for each individual. While this characteristic of our
study design allowed us to obtain a more precise picture of
the relationship between hypercoagulability, inflammation
and hemolysis, it also precluded us from performing all
assays in all patients, because of limited availability of
mRNA, plasma and serum. Since the exclusion of samples
from some of the assays was completely at random, we do
not expect that this introduced any bias in our analysis.
In summary, our results demonstrate the presence of a
hypercoagulable state in HbSC patients, although this
hypercoagulability is less intense than that seen in SCA.
As in SCA, inflammation and hemolysis seem to have
causative roles in the hemostatic activation in HbSC dis-
ease, but additional unique factors may also be involved.
Given the high prevalence and morbidity of thrombotic
complications in this population, we believe that future
studies should focus on a better understanding of the
pathophysiology of hypercoagulability in HbSC disease.
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